
Lipocine LPCN
$ 7.15
-3.38%
Quarterly report 2025-Q3
added 11-06-2025
Lipocine Total Non Current Liabilities 2011-2026 | LPCN
Annual Total Non Current Liabilities Lipocine
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 3.43 M | 8.41 M | 6.93 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.41 M | 3.43 M | 6.25 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Verastem
VSTM
|
108 M | $ 5.04 | -4.73 % | $ 349 M | ||
|
VistaGen Therapeutics
VTGN
|
4.16 M | $ 0.57 | -5.87 % | $ 17.6 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
263 M | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
Xenon Pharmaceuticals
XENE
|
12.3 M | $ 54.48 | -1.89 % | $ 4.24 B | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | ||
|
Enochian Biosciences
ENOB
|
425 K | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Summit Therapeutics
SMMT
|
5.71 M | $ 16.58 | -3.94 % | $ 12.4 B | ||
|
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
604 M | $ 317.36 | -3.29 % | $ 41.6 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.29 | -3.6 % | $ 822 M | ||
|
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | ||
|
Calithera Biosciences
CALA
|
4.82 M | - | -10.95 % | $ 876 K | ||
|
Fusion Pharmaceuticals
FUSN
|
4.31 M | - | - | $ 1.41 B | ||
|
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | ||
|
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 19.01 | -2.66 % | $ 889 M | ||
|
Gritstone Oncology
GRTS
|
30.5 M | - | 0.42 % | $ 213 M | ||
|
Завод ДИОД
DIOD
|
89.5 M | - | - | - | ||
|
Фармсинтез
LIFE
|
13.2 M | - | - | - | ||
|
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 20.75 | -3.35 % | $ 3.44 B | ||
|
Aligos Therapeutics
ALGS
|
15 M | $ 6.66 | -5.4 % | $ 65.8 M | ||
|
Teligent, Inc.
TLGT
|
142 M | - | -13.85 % | $ 16.1 M | ||
|
Viela Bio, Inc.
VIE
|
1.38 M | - | - | $ 2.91 B | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
Alkermes plc
ALKS
|
329 M | $ 29.39 | -1.77 % | $ 4.84 B | ||
|
Cabaletta Bio
CABA
|
43.9 M | $ 2.68 | -4.96 % | $ 269 M | ||
|
AbbVie
ABBV
|
81.7 B | $ 209.4 | -0.81 % | $ 370 B | ||
|
AbCellera Biologics
ABCL
|
326 M | $ 3.27 | -2.39 % | $ 977 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M |